PEP 010 - PEP-TherapyAlternative Names: DPT C9h; PEP-010
Latest Information Update: 25 Jul 2016
At a glance
- Originator PEP-Therapy
- Class Peptides
- Mechanism of Action Caspase 9 inhibitors; Protein phosphatase 2A inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 25 Jul 2016 Preclinical trials in Cancer in France (unspecified route)